Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Ensem Therapeutics
Ensem Therapeutics
Mayo Clinic
Eli Lilly and Company
Neonc Technologies, Inc.
Rutgers, The State University of New Jersey
Terremoto Biosciences Inc.
Bristol-Myers Squibb
Sichuan Enray Pharmaceutical Sciences Company
National Institutes of Health Clinical Center (CC)
Theravectys S.A.
Radiopharm Theranostics, Ltd
Ocellaris Pharma, Inc.
National Institutes of Health Clinical Center (CC)
Tanabe Pharma America, Inc.
DualityBio Inc.
LigaChem Biosciences, Inc.
Incyte Corporation
Yuhan Corporation
Marengo Therapeutics, Inc.
ModeX Therapeutics, An OPKO Health Company
Cancer Research UK
Klus Pharma Inc.
Precision Biologics, Inc
RAPT Therapeutics, Inc.
UNICANCER
Taiho Oncology, Inc.
Aminex Therapeutics, Inc.
NextCure, Inc.
NGM Biopharmaceuticals, Inc
Cancer Research UK
SCG Cell Therapy Pte. Ltd.
Second Affiliated Hospital of Guangzhou Medical University
Innolake Biopharm
GeneMedicine Co., Ltd.
Evopoint Biosciences Inc.
Dana-Farber Cancer Institute
Klus Pharma Inc.
Advaxis, Inc.
Incyte Corporation
Seagen Inc.
NKGen Biotech, Inc.
National Institutes of Health Clinical Center (CC)
University of Plymouth